{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:50Z","timestamp":1790270750545,"version":"4.1.0"},"reference-count":63,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2019,7,31]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Immune checkpoint inhibitors are revolutionized drugs for cancer immunotherapy in\nthe last years. The mechanism of action of CPIs including the limitation of the activation of Tcells,\nand thus enhancing the self-immune response against tumour cells. Checkpointinhibitors(\nCPIs) may dysregulate the immune system, resulting in some toxicities. These toxicities\nor side effects are called Immune-related Adverse Events (IRAEs) that can potentially affect\nany organ and tissue. Rheumatic diseases due to checkpoint inhibitors are also reported in\nthe literature. The spectrum of rheumatic manifestations are quite wide; the most common are\narthralgia\/arthritis, myalgia\/myositis, polimyalgia rheumatica, lupus, rheumatoid arthritis,\nSj\u00f6gren\u2019s syndrome. At the same time, these drugs can also cause an exacerbation of known\nrheumatologic disease. Treatment approaches for developing rheumatic findings due to checkpoint\ninhibitors should be multidisciplinary. There should be a close relationship between oncologists\nwho follow-up these patients and rheumatologists. The rheumatic manifestations\nshould be defined and treated early. In general, the musculoskeletal side effects are transient and\nmay regress after stopping CPIs. The most commonly used medications are corticosteroids. Immunosuppressive\ndrugs (HQ, MTX, anti-TNF-alpha, anti-IL-6) should be preferred when treatment\nis unresponsive or as steroid-sparing agents.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>The aim of this review was to evaluate the checkpoint inhibitors-related rheumatologic findings and\ntherapeutic strategies in light of recent literature data.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573397115666190119094736","type":"journal-article","created":{"date-parts":[[2019,1,19]],"date-time":"2019-01-19T19:34:43Z","timestamp":1547926483000},"page":"201-208","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?"],"prefix":"10.2174","volume":"15","author":[{"given":"Fusun","family":"Gediz","sequence":"first","affiliation":[{"name":"Department of Hematology, Transplantation Unit, Izmir Training and Research Hospital, Bone Marrow, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senol","family":"Kobak","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Istinye University Faculty of Medicine, Liv Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"340","author":"Davidson A.","year":"2001","unstructured":"Davidson A.;  Autoimmune diseases 2001,340-345","journal-title":"Autoimmune diseases"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.autrev.2004.07.004","volume":"3","author":"Abbas A.K.","year":"2004","unstructured":"Abbas A.K.; Lohr J.; Knoechel B.; Nagabhushanam V.; T cell tolerance and autoimmunity. Autoimmun Rev 2004,3(7-8),471-475","journal-title":"Autoimmun Rev"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.autrev.2008.04.007","volume":"7","author":"Davies A.J.","year":"2008","unstructured":"Davies A.J.; Immunological tolerance and the autoimmune response. Autoimmun Rev 2008,7(7),538-543","journal-title":"Autoimmun Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/ni0901-759","volume":"2","author":"Ermann J.","year":"2001","unstructured":"Ermann J.; Fathman C.G.; Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2001,2(9),759-761","journal-title":"Nat Immunol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.290.5489.84","volume":"290","author":"Ravetch J.V.","year":"2000","unstructured":"Ravetch J.V.; Lanier L.L.; Immune inhibitory receptors. Science 2000,290(5489),84-89","journal-title":"Science"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jaut.2008.04.009","volume":"31","author":"Lleo A.","year":"2008","unstructured":"Lleo A.; Selmi C.; Invernizzi P.; Podda M.; Gershwin M.E.; The consequences of apoptosis in autoimmunity. J Autoimmun 2008,31(3),257-262","journal-title":"J Autoimmun"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"Michot J.M.","year":"2016","unstructured":"Michot J.M.; Bigenwald C.; Champiat S.; Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016,54,139-148","journal-title":"Eur J Cancer"},{"key":"ref=8","unstructured":"US National Cancer Institute"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrrheum.2016.131","volume":"12","author":"van der Vlist M.","year":"2016","unstructured":"van der Vlist M.; Kuball J.; Radstake T.R.; Meyaard L.; Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol 2016,12(10),593-604","journal-title":"Nat Rev Rheumatol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"Couzin-Frankel J.","year":"2013","unstructured":"Couzin-Frankel J.; Breakthrough of the year 2013. Cancer immunotherapy. Science 2013,342(6165),1432-1433","journal-title":"Science"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.coi.2008.09.001","volume":"20","author":"Meffre E.","year":"2008","unstructured":"Meffre E.; Wardemann H.; B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008,20(6),632-638","journal-title":"Curr Opin Immunol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"Pardoll D.M.","year":"2012","unstructured":"Pardoll D.M.; The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012,12(4),252-264","journal-title":"Nat Rev Cancer"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"19;363","author":"Hodi FS","year":"2010","unstructured":"Hodi FS; O'Day SJ; McDermott DF; Weber RW; Sosman JA; Haanen JB; Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010,19;363(8),711-23","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","volume":"384","author":"Robert C.","year":"2014","unstructured":"Robert C.; Ribas A.; Wolchok J.D.; Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014,384(9948),1109-1117","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"Robert C.","year":"2015","unstructured":"Robert C.; Long G.V.; Brady B.; Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015,372(4),320-330","journal-title":"N Engl J Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"Fehrenbacher L.","year":"2016","unstructured":"Fehrenbacher L.; Spira A.; Ballinger M.; Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016,387(10030),1837-1846","journal-title":"Lancet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5575","DOI":"10.4049\/jimmunol.175.9.5575","volume":"175","author":"van Gaalen F.","year":"2005","unstructured":"van Gaalen F.; Ioan-Facsinay A.; Huizinga T.W.; Toes R.E.; The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J Immunol 2005,175(9),5575-5580","journal-title":"J Immunol"},{"key":"ref=18","first-page":"693","volume":"107","author":"Cooper G.S.","year":"1999","unstructured":"Cooper G.S.; Miller F.W.; Pandey J.P.; The role of genetic factors in autoimmune disease: implications for environmental research. Environ Health Perspect 1999,107(Suppl. 5),693-700","journal-title":"Environ Health Perspect"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","volume":"50","author":"Nielen M.M.","year":"2004","unstructured":"Nielen M.M.; van Schaardenburg D.; Reesink H.W.; Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004,50(2),380-386","journal-title":"Arthritis Rheum"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1002\/art.24038","volume":"58","author":"Koenig M.","year":"2008","unstructured":"Koenig M.; Joyal F.; Fritzler M.J.; Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud\u2019s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008,58(12),3902-3912","journal-title":"Arthritis Rheum"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/nrrheum.2014.6","volume":"10","author":"Deane K.D.","year":"2014","unstructured":"Deane K.D.; El-Gabalawy H.; Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol 2014,10(4),212-228","journal-title":"Nat Rev Rheumatol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.autrev.2018.01.010","volume":"17","author":"Tocut M.","year":"2018","unstructured":"Tocut M.; Brenner R.; Zandman-Goddard G.; Autoimmune phenomena and disease in cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev 2018,17(6),610-616","journal-title":"Autoimmun Rev"},{"key":"ref=23","volume":"28;13","author":"Guo Y","year":"2018","unstructured":"Guo Y; Walsh AM; Canavan M; Wechalekar MD; Cole S; Yin X; Immune checkpoint inhibitor PD-1 pathway is downregulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS One 2018,28;13(2)","journal-title":"PLoS One"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","volume":"17","author":"Liu C.","year":"2015","unstructured":"Liu C.; Jiang J.; Gao L.; Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. Arthritis Res Ther 2015,17,340","journal-title":"Arthritis Res Ther"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"Nishimura H.","year":"1999","unstructured":"Nishimura H.; Nose M.; Hiai H.; Minato N.; Honjo T.; Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999,11(2),141-151","journal-title":"Immunity"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clim.2013.11.007","volume":"150","author":"Olde Nordkamp M.J.","year":"2014","unstructured":"Olde Nordkamp M.J.; Koeleman B.P.; Meyaard L.; Do inhibitory immune receptors play a role in the etiology of autoimmune disease? Clin Immunol 2014,150(1),31-42","journal-title":"Clin Immunol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.semarthrit.2017.10.018","volume":"47","author":"Kuswanto W.F.","year":"2018","unstructured":"Kuswanto W.F.; MacFarlane L.A.; Gedmintas L.; Mulloy A.; Choueiri T.K.; Bermas B.L.; Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. Semin Arthritis Rheum 2018,47(6),907-910","journal-title":"Semin Arthritis Rheum"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/CJI.0000000000000060","volume":"38","author":"Chan M.M.","year":"2015","unstructured":"Chan M.M.; Kefford R.F.; Carlino M.; Clements A.; Manolios N.; Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. J Immunother 2015,38(1),37-39","journal-title":"J Immunother"},{"key":"ref=29","author":"Shah M.","year":"2018","unstructured":"Shah M.; Tayar J.H.; Abdel-Wahab N.; Suarez-Almazor M.E.; Myositis as an adverse event of immune checkpoint blockadefor cancer therapy. Semin Arthritis Rheum Epub ahead of print2018","journal-title":"Semin Arthritis Rheum"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1111\/1346-8138.12991","volume":"42","author":"Yoshioka M.","year":"2015","unstructured":"Yoshioka M.; Kambe N.; Yamamoto Y.; Suehiro K.; Matsue H.; Case of respiratory discomfort due to myositis after administration of nivolumab. J Dermatol 2015,42(10),1008-1009","journal-title":"J Dermatol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","volume":"151","author":"Sheik Ali S.","year":"2015","unstructured":"Sheik Ali S.; Goddard A.L.; Luke J.J.; Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade. JAMA Dermatol 2015,151(2),195-199","journal-title":"JAMA Dermatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","volume":"4","author":"Khoja L.","year":"2016","unstructured":"Khoja L.; Maurice C.; Chappell M.; Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016,4(3),175-178","journal-title":"Cancer Immunol Res"},{"key":"ref=33","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000412","volume":"3","author":"Calabrese C.","year":"2017","unstructured":"Calabrese C.; Kirchner E.; Kontzias K.; Velcheti V.; Calabrese L.H.; Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. RMD Open 2017,3(1)","journal-title":"RMD Open"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1634\/theoncologist.2016-0390","volume":"22","author":"Naidoo J.","year":"2017","unstructured":"Naidoo J.; Cappelli L.C.; Forde P.M.; Inflammatory arthritis: A newly recognized adverse event of immune checkpoint blockade. Oncologist 2017,22(6),627-630","journal-title":"Oncologist"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000454875","volume":"9","author":"Jaberg-Bentele N.F.","year":"2017","unstructured":"Jaberg-Bentele N.F.; Kunz M.; Abuhammad S.; Dummer R.; Flare-up of rheumatoid rrthritis by anti-CTLA-4 antibody but not by anti-PD1 therapy in a patient with metastatic melanoma. Case Rep Dermatol 2017,9(1),65-68","journal-title":"Case Rep Dermatol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3899\/jrheum.110054","volume":"38","author":"Wells A.F.","year":"2011","unstructured":"Wells A.F.; Westhovens R.; Reed D.M.; Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. J Rheumatol 2011,38(11),2362-2368","journal-title":"J Rheumatol"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2015-000032","volume":"1","author":"Aya F.","year":"2016","unstructured":"Aya F.; Gaba L.; Victoria I.; Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. ESMO Open 2016,1(1)","journal-title":"ESMO Open"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/art.39406","volume":"68","author":"de Velasco G.","year":"2016","unstructured":"de Velasco G.; Bermas B.; Choueiri T.K.; Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol 2016,68(2),556-557","journal-title":"Arthritis Rheumatol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","volume":"76","author":"Cappelli L.C.","year":"2017","unstructured":"Cappelli L.C.; Gutierrez A.K.; Baer A.N.; Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017,76(1),43-50","journal-title":"Ann Rheum Dis"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13256-018-1579-1","volume":"26;12","author":"Ngo L","year":"2018","unstructured":"Ngo L; Miller E; Valen P; Gertner E; Nivolumab induced remitting\nseronegative symmetrical synovitis with pitting edema in a patient\nwith melanoma: a case report. J Med Case Rep 2018,26;12(1),48","journal-title":"J Med Case Rep"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/art.38282","volume":"66","author":"Goldstein B.L.","year":"2014","unstructured":"Goldstein B.L.; Gedmintas L.; Todd D.J.; Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol 2014,66(3),768-769","journal-title":"Arthritis Rheumatol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fimmu.2018.00315","volume":"9","author":"Hid Cadena R.","year":"2018","unstructured":"Hid Cadena R.; Abdulahad W.H.; Hospers G.A.P.; Checks and balances in autoimmune vasculitis. Front Immunol 2018,9,315","journal-title":"Front Immunol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1200\/JCO.2012.47.5095","volume":"31","author":"Minor D.R.","year":"2013","unstructured":"Minor D.R.; Bunker S.R.; Doyle J.; Lymphocytic vasculitis of the uterus in a patient with melanoma receiving ipilimumab. J Clin Oncol 2013,31(20),e356-e6","journal-title":"J Clin Oncol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40425-014-0041-1","volume":"2","author":"Manusow J.S.","year":"2014","unstructured":"Manusow J.S.; Khoja L.; Pesin N.; Joshua A.M.; Mandelcorn E.D.; Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma. J Immunother Cancer 2014,2(1),41","journal-title":"J Immunother Cancer"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kes034","volume":"51","author":"Wilde B.","year":"2012","unstructured":"Wilde B.; Hua F.; Dolff S.; Aberrant expression of the negative costimulator PD-1 on T cells in granulomatosis with polyangiitis. Rheumatology (Oxford) 2012,51(7),1188-1197","journal-title":"Rheumatology (Oxford)"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.clim.2008.03.506","volume":"128","author":"Slot M.C.","year":"2008","unstructured":"Slot M.C.; Sokolowska M.G.; Savelkouls K.G.; Janssen R.G.J.H.; Damoiseaux J.G.M.C.; Tervaert J.W.; Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis. Clin Immunol 2008,128(1),39-45","journal-title":"Clin Immunol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","volume":"55","author":"van den Brom R.R.H.","year":"2016","unstructured":"van den Brom R.R.H.; Abdulahad W.H.; Rutgers A.; Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford) 2016,55(6),1143-1145","journal-title":"Rheumatology (Oxford)"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00262-014-1607-y","volume":"63","author":"Pedersen M.","year":"2014","unstructured":"Pedersen M.; Andersen R.; N\u00f8rgaard P.; Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother 2014,63(12),1341-1346","journal-title":"Cancer Immunol Immunother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.1111\/jdv.14217","volume":"31","author":"Ruiz-Ba\u00f1obre J.","year":"2017","unstructured":"Ruiz-Ba\u00f1obre J.; Garc\u00eda-Gonz\u00e1lez J.; Anti-PD-1\/PD-L1-induced psoriasis from an oncological perspective. J Eur Acad Dermatol Venereol 2017,31(9),e407-e408","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1093\/rheumatology\/kew281","volume":"55","author":"Law-Ping-Man S.","year":"2016","unstructured":"Law-Ping-Man S.; Martin A.; Briens E.; Tisseau L.; Safa G.; Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer. Rheumatology (Oxford) 2016,55(11),2087-2089","journal-title":"Rheumatology (Oxford)"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/1744666X.2014.878649","volume":"10","author":"Wofford J.","year":"2014","unstructured":"Wofford J.; Menter A.; Ustekinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol 2014,10(2),189-202","journal-title":"Expert Rev Clin Immunol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","volume":"92","author":"Barbosa N.S.","year":"2017","unstructured":"Barbosa N.S.; Wetter D.A.; Wieland C.N.; Shenoy N.K.; Markovic S.N.; Thanarajasingam U.; Scleroderma induced by pembrolizumab: A case series. Mayo Clin Proc 2017,92(7),1158-1163","journal-title":"Mayo Clin Proc"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMc0904283","volume":"361","author":"Fadel F.","year":"2009","unstructured":"Fadel F.; El Karoui K.; Knebelmann B.; Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009,361(2),211-212","journal-title":"N Engl J Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1182\/blood-2005-06-2298","volume":"106","author":"Lute K.D.","year":"2005","unstructured":"Lute K.D.; May K.F.; Lu P.; Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 2005,106(9),3127-3133","journal-title":"Blood"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"Zimmer L.","year":"2016","unstructured":"Zimmer L.; Goldinger S.M.; Hofmann L.; Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016,60,210-225","journal-title":"Eur J Cancer"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"Gutzmer R.","year":"2017","unstructured":"Gutzmer R.; Koop A.; Meier F.; Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer 2017,75,24-32","journal-title":"Eur J Cancer"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"Johnson D.B.","year":"2016","unstructured":"Johnson D.B.; Sullivan R.J.; Ott P.A.; Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol 2016,2(2),234-240","journal-title":"JAMA Oncol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"21; 5","author":"Puzanov I","year":"2017","unstructured":"Puzanov I; Diab A; Abdallah K; Bingham CO; Brogdon C; Dadu R; Managing toxicities associated with immune checkpoint inhibitors:\nconsensus recommendations from the Society for Immunotherapy\nof Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017,21; 5(1),95","journal-title":"J Immunother Cancer"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrrheum.2016.131","volume":"12","author":"van der Vlist M.","year":"2016","unstructured":"van der Vlist M.; Kuball J.; Radstake T.R.; Meyaard L.; Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat Rev Rheumatol 2016,12(10),593-604","journal-title":"Nat Rev Rheumatol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"Champiat S.","year":"2016","unstructured":"Champiat S.; Lambotte O.; Barreau E.; Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016,27(4),559-574","journal-title":"Ann Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/CMR.0b013e32835fb524","volume":"23","author":"Pag\u00e8s C.","year":"2013","unstructured":"Pag\u00e8s C.; Gornet J.M.; Monsel G.; Ipilimumab-induced acute severe colitis treated by infliximab. Melanoma Res 2013,23(3),227-230","journal-title":"Melanoma Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1060028014528152","volume":"48","author":"Merrill S.P.","year":"2014","unstructured":"Merrill S.P.; Reynolds P.; Kalra A.; Biehl J.; Vandivier R.W.; Mueller S.W.; Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother 2014,48(6),806-810","journal-title":"Ann Pharmacother"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1136\/annrheumdis-2017-211560","volume":"76","author":"Kim S.T.","year":"2017","unstructured":"Kim S.T.; Tayar J.; Trinh V.A.; Suarez-Almazor M.; Garcia S.; Hwu P.; Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Ann Rheum Dis 2017,76(12),2061-2064","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T19:51:51Z","timestamp":1567972311000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169153\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,31]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7,31]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397115666190119094736","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,31]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}